- Home
- RARE vs PTY Comparison
RARE vs PTY Comparison
Compare RARE & PTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- PTY
- Stock Information
- Founded
- RARE 2010
- PTY 2002
- Country
- RARE United States
- PTY United States
- Employees
- RARE N/A
- PTY N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- PTY Investment Managers
- Sector
- RARE Health Care
- PTY Finance
- Exchange
- RARE Nasdaq
- PTY Nasdaq
- Market Cap
- RARE 3.1B
- PTY 2.8B
- IPO Year
- RARE 2014
- PTY N/A
- Fundamental
- Price
- RARE $33.28
- PTY $13.83
- Analyst Decision
- RARE Strong Buy
- PTY
- Analyst Count
- RARE 13
- PTY 0
- Target Price
- RARE $87.69
- PTY N/A
- AVG Volume (30 Days)
- RARE 1.5M
- PTY 550.4K
- Earning Date
- RARE 11-03-2025
- PTY 01-01-0001
- Dividend Yield
- RARE N/A
- PTY 9.65%
- EPS Growth
- RARE N/A
- PTY N/A
- EPS
- RARE N/A
- PTY N/A
- Revenue
- RARE $610,159,000.00
- PTY N/A
- Revenue This Year
- RARE $19.72
- PTY N/A
- Revenue Next Year
- RARE $23.29
- PTY N/A
- P/E Ratio
- RARE N/A
- PTY N/A
- Revenue Growth
- RARE 26.77
- PTY N/A
- 52 Week Low
- RARE $25.81
- PTY $11.92
- 52 Week High
- RARE $56.38
- PTY $14.88
- Technical
- Relative Strength Index (RSI)
- RARE 58.42
- PTY 40.16
- Support Level
- RARE $32.40
- PTY $13.07
- Resistance Level
- RARE $34.78
- PTY $14.38
- Average True Range (ATR)
- RARE 1.26
- PTY 0.23
- MACD
- RARE 0.27
- PTY -0.11
- Stochastic Oscillator
- RARE 71.21
- PTY 46.60
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About PTY Pimco Corporate & Income Opportunity Fund
PIMCO Corporate & Income Opportunity Fds operates as a closed-end management investment company. It seeks to maximize total return through a combination of current income and capital appreciation. The fund invests a majority of the total assets in a combination of corporate debt obligations of varying maturities, other corporate income-producing securities, and income-producing securities of non-corporate issuers, such as U.S. Government securities, municipal securities, and mortgage-backed and other asset-backed securities issued on a public or private basis.